---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-020822"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2023-06-12T23:59:59+00:00"
generated_at: "2026-06-14T02:52:33.740900+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bioxytran secures $500k equity investment from Triton Funds for COVID-19 trial funding

## Summary
- Triton Funds LP to purchase 1,612,903 shares at $0.31/share, totaling $500,000.
- Proceeds will fund dosage optimization study for mild-moderate COVID-19; dosing expected within month.
- Funding sufficient to reach Phase 3 regulatory submission milestone in India.
- Triton is second institutional investor alongside Walleye Capital (over $5B AUM).
- Company also amended WallachBeth engagement for brokerage of notes totaling $1.165M.

## SEC filing metadata
- accession: 0001493152-23-020822
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2023-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315223020822/0001493152-23-020822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315223020822/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-020822
- JSON: https://secwatch.observer/filing/0001493152-23-020822.json
- Plain text: https://secwatch.observer/filing/0001493152-23-020822.txt

## Key facts
- Material Agreements
  BIOXYTRAN, INC entered into Common Stock Closing Agreement with Triton Funds LP valued at Purchase of 1,612,903 shares for $500,000 (approx. $0.31 per share) (effective 2023-06-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Triton Funds LP
  - Value: Purchase of 1,612,903 shares for $500,000 (approx. $0.31 per share)
  - Effective: 2023-06-08
  source text: On June 8, 2023, Bioxytran, Inc. (the “Company”) entered into a common stock closing agreement (the “Closing Agreement”) with Triton Funds LP (“Triton”). Pursuant to the Closing Agreement, subject to certain conditions set forth in the Closing Agreement, Triton will purchase one million six hundred twelve thousand nine hundred three (1,612,903) shares of the Company’s Common Stock for an amount of five hundred thousand dollars ($500,000), or $0.31 per share (the “Closing Price”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445815/000149315223020822/0001493152-23-020822-index.htm
- Material Agreements
  BIOXYTRAN, INC entered into Amended Engagement Letter with WallachBeth Capital LLC valued at Brokerage of three notes totaling $1,165,000, with issuance of 800,000 warrants exercisable at $0.20 (effective 2023-05-08).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: WallachBeth Capital LLC
  - Value: Brokerage of three notes totaling $1,165,000, with issuance of 800,000 warrants exercisable at $0.20
  - Effective: 2023-05-08
  source text: On May 8, 2023, Bioxytran, Inc. (the “Company”) signed an amended engagement letter (the “Engagement Agreement”) with WallachBeth Capital LLC (“WallachBeth”) to brokerage a deal for three (3) of Company’s outstanding Notes, for a total value of one million one hundred sixty-five thousand dollars ($1,165,000).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445815/000149315223020822/0001493152-23-020822-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.